New and emerging treatments for ulcerative colitis: a focus on vedolizumab
Open Access
- 1 May 2013
- journal article
- review article
- Published by Informa UK Limited in Biologics: Targets and Therapy
- Vol. 7, 123-130
- https://doi.org/10.2147/btt.s30416
Abstract
New and emerging treatments for ulcerative colitis: a focus on vedolizumab Tamsin Gledhill,1 Keith Bodger21Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UK Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified.Keywords: inflammatory bowel disease, effectiveness, integrin antagonistsKeywords
This publication has 32 references indexed in Scilit:
- Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximabAlimentary Pharmacology & Therapeutics, 2010
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesJournal of Pharmacology and Experimental Therapeutics, 2009
- Maintenance treatment with infliximab for the management of Crohn’s disease in adultsBiologics: Targets and Therapy, 2009
- Adalimumab for the treatment of Crohn’s diseaseBiologics: Targets and Therapy, 2008
- MLN-02 in IBD: Is “Super-selective” really super?Gastroenterology, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Expression of lymphocyte-endothelial receptor-ligand pairs, alpha 4beta 7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel diseaseGut, 1999
- Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7Gastroenterology, 1996
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Variation Between Observers in Describing Mucosal Appearances in ProctocolitisBMJ, 1964